
The Oregonian recently published an article concerning a promising new drug to treat Parkinson’s Disease!
The drug, PRX002, is a humanized monoclonal antibody that targets alpha-synuclein and prevents neuron-to-neuron transfer of toxic aggregates. In other words; These proteins, known as alpha-synuclein, clump into formations called Lewy bodies, which kill neurons in the brain. The new drug builds on research in mice that show it is possible to reduce the presence of alpha-synuclein proteins, which in turn reduces Parkinson’s Disease symptoms. Continue reading “Could a New Drug Unlock the Mystery of Parkinson’s Disease?”


